Syneron Announces International Launch of eLase(TM) Laser Hair Removal System
08 Noviembre 2011 - 7:00PM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic
device company, announced today the International launch of the
eLase™ with Motif™ laser hair removal system. The eLase system will
be unveiled at CosmoProf Asia 2011, November 9-11, 2011. The eLase
system has received CE Mark approval from the European Union and is
available in select European and Asian markets.
The eLase system combines Syneron's proprietary elos bi-polar
radio frequency (RF) energy with diode laser energy. This
synergistic energy combination allows the system to utilize less
optical energy during treatments, increasing patient safety for all
skin types. The system features the new Motif
LHR hair removal applicator with Motif mode that leverages the
energy combination to allow high frequency, lower energy treatments
that are virtually pain free with far shorter treatment times than
competitive devices. The system also includes a new Motif IR applicator that can be used for fractional
facial rejuvenation procedures with zero patient downtime,
expanding the capabilities of the eLase system beyond hair removal
procedures.
Louis P. Scafuri, Chief Executive Officer of Syneron Medical,
said, "The eLase builds upon Syneron and Candela's proven track
record of best-in-class hair removal systems with a next-generation
platform designed to further enhance the patient experience. The
unique combination of our elos technology allows for selective and
deep dermal penetration, providing highly effective and safe hair
removal treatments for patients of all skin types. In addition, the
eLase features many ease-of-use and patient comfort enhancements,
including faster treatment times, a new pain free mode, contact
cooling and intra-procedure dermal monitoring."
Mr. Scafuri further added, "In addition to the hair removal
mode, the system also has an optional Motif IR applicator that
allows the practice to leverage the eLase to offer fractional skin
rejuvenation procedures with the same platform and same safety
profile across skin types. The eLase system is available through
our direct sales force and distribution partners in Europe and
Asia."
About Cosmoprof Asia 2011 Cosmoprof Asia
is the leading business-to-business beauty trade show event in
Asia. Exhibits are divided into five themed sectors that cover the
entire spectrum of the beauty industry. This exhibition features
the latest trends and products from within all segments of the
beauty and wellness industry. Strong International participation is
confirmed by the presence of national and group pavilions,
providing a global perspective on emerging trends.
About Syneron Medical Ltd. Syneron Medical
Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company
with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and
the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel.
Syneron also has R&D and manufacturing operations in the US.
The Company markets, services and supports its products in 90
countries. It has offices in North America, France, Germany, Italy,
Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and
distributors worldwide.
Investor Contacts: Asaf Alperovitz Chief Financial
Officer + 972 73 244 2283 Email: Email Contact Zack Kubow The Ruth
Group 646-536-7020 Email: Email Contact
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024